Bayer Investor Relations

Team having a chat
Investor News
Share Price / Index
May 12, 2026
First quarter of 2026:
Bayer reports solid start to the year and confirms currency-adjusted Group guidance for 2026
May 06, 2026
Not intended for UK Media
Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline
April 29, 2026
Not intended for U.S. and UK Media
China’s Center of Drug Evaluation accepts marketing authorization application for Bayer’s FXIa inhibitor in stroke prevention after a non-cardioembolic ischemic stroke or transient ischemic attack